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Levosimendan and systemic 
vascular resistance in cardiac 
surgery patients: a systematic 
review and meta-analysis
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Dominik Guensch  1, thierry carrel2, Balthasar eberle1 & Gabor erdoes1*
Levosimendan is a potent non-adrenergic inodilator agent. The net effect of hemodynamic changes 
may result in a hyperdynamic state with low systemic vascular resistance. We conducted a systematic 
review and meta-analysis assessing hemodynamics in cardiac surgery patients treated with 
levosimendan. English-language literature was searched systematically from 2006 until October 2018, 
including randomized controlled trials and case-matched or retrospective studies providing at least 
two sequentially measured hemodynamic variables in adult patients who underwent cardiac surgery 
with cardiopulmonary bypass and were treated with levosimendan in comparison to alternative drugs 
or devices. Cardiac index significantly increased in the levosimendan group by 0.74 (0.24 to 1.23) 
[standardized mean difference (95% CI); p = 0.003] from baseline to postoperative day (POD) 1, and 
by 0.75 (0.25 to 1.25; p = 0.003) from baseline to POD 7, when corrected for the standardized mean 
difference at baseline by a multivariate mixed effects meta-analysis model. With this correction for 
baseline differences, other hemodynamic variables including systemic vascular resistance did not 
significantly differ until POD 1 [−0.17 (−0.64 to 0.30), p = 0.48] and POD 7 [−0.13 (−0.61 to 0.34), 
p = 0.58] between the levosimendan and the comparator group. Levosimendan increases cardiac 
index in patients undergoing cardiac surgery. Although levosimendan has inodilator properties, this 
meta-analysis finds no clinical evidence that levosimendan produces vasopressor-resistant vasoplegic 
syndrome.
Levosimendan exerts its inodilatory effects mainly through three mechanisms of action: calcium sensitization, 
opening of adenosine triphosphate-dependent-potassium (KATP) channels in vascular smooth muscle cells and in 
the mitochondria of cardiomyocytes1. Through calcium sensitization, levosimendan has positive inotropic effects 
which result in an increase of cardiac output, whereas its action on KATP channels causes systemic vasodilation in 
both arterial and venous vascular beds (Fig. 1)2–4.
In recent years, levosimendan has been extensively studied in cardiac surgery. In the majority of studies, it 
was administered as a preoperative bolus, often immediately after anesthesia induction to exploit its precondi-
tioning effect before surgery5–8. A high plasma concentration achieved in a short period of time may significantly 
lower systemic vascular resistance, since levosimendan acts on vascular smooth muscle cells in a dose-dependent 
fashion9.
It is known that continued preoperative intake of angiotensin-converting enzyme inhibitors or beta-blockers, 
low pre-operative left ventricular ejection fraction (EF), vasopressor use prior to cardiopulmonary bypass (CPB) 
and prolonged duration of CPB are predisposing factors for abnormally low systemic vascular resistance after 
cardiac surgery10,11. The related syndrome, post-cardiotomy vasoplegia, has been defined as hypotension in the 
absence of a low cardiac output state12, and is associated with prolonged hospital stay and increased mortality, 
mainly due to the resulting end-organ failure. Although the etiology of post-cardiotomy vasoplegia is probably 
multifactorial, and its mechanisms are not completely understood, studies ascribe a relevant contribution to the 
CPB circuit itself. The exposure of blood to the foreign surfaces triggers a proinflammatory response, with release 
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of vasoactive mediators that may disturb baseline vascular reactivity and tonus. Patients with heart failure express 
high levels of inflammatory mediators and may therefore be particularly susceptible to vasodilatory effects of 
drugs13. It is precisely this subgroup of patients who frequently receive levosimendan in the perioperative period. 
Thus, short-term loading of levosimendan in the pre-CPB period, especially administered by bolus injection, may 
be counterproductive due to a high incidence of hypotension with subsequent need of vasopressor medication.
Recent meta-analyses on levosimendan indicate that its administration in cardiac surgery patients is associ-
ated with decreased incidence of acute renal injury and renal replacement therapy and a lower 30-d mortality, 
Figure 1. Descriptive figure illustrating mechanism of action and hemodynamic effects associated with 
levosimendan administration. CI, cardiac index; EF, ejection fraction; SVR, systemic vascular resistence; MAP, 
mean arterial pressure; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure.
Figure 2. Study flow chart with numbers of abstracts screened and studies assessed for eligibility and included 
in the review; reasons for exclusions at each stage are also given.
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especially in those presenting with reduced left ventricular contractility14–18. Beyond its unequivocally proven 
positive inotropism, however, levosimendan’s net effect on global hemodynamics of patients undergoing cardiac 
surgery with CPB remains controversial.
We performed a study-level meta-analysis of the available literature. Our aim was to investigate hemodynamic 
parameters - especially those indicating vasoplegia - in the context of perioperative levosimendan administration 
in patients undergoing cardiac surgery with CPB.
Study First author, year Type Patients Surgery Bolus Infusion Subgroups Comparator
1. Anastasiadis, 2016 RCT 32 Comb No pre-surgery 1 placebo
2. Atalay, 2016 RCT 58 CABG pre-surgery pre-surgery 1 placebo
3. Eris, 2014 RS 40 CABG no/post-CPB pre-surgery/post-CPB 3 placebo
4. Sharma, 2014 RCT 40 Comb pre-surgery No 1 placebo
5. Erb, 2014 RCT 33 Comb No pre-surgery 1 placebo
6. Ersoy, 2013 RCT 20 Comb pre-surgery pre-surgery 1 placebo
7. Lomivorotov, 2012 RCT 90 Comb pre-surgery pre-surgery 2 IABP
8. Levin, 2012 RCT 252 CABG pre-surgery pre-surgery 1 placebo
9. Severi, 2011 CM 22 CABG No pre-surgery 1 IABP
10. Leppinkangas, 2011 RCT 24 Comb pre-surgery pre-surgery 1 placebo
11. Lahtinen, 2011 RCT 200 Comb pre-surgery pre-surgery 1 placebo
12. Triapepe, 2009 RCT 102 CABG pre-surgery No 1 placebo
13. Eriksson, 2009 RCT 60 CABG pre-surgery pre-surgery 1 placebo
14. Jarvela, 2008 RCT 24 Comb No pre-surgery 1 placebo
15. Triapepe, 2006 RCT 24 CABG pre-surgery No 1 placebo
16. Sahu, 2016 RCT 30 CABG pre-surgery pre-surgery 1 nitroglycernine
Table 1. Main descriptors of the studies included in meta-analysis. Legend: RCT, randomized controlled trial; 
RS, retrospective study; CM, case-matched study; CABG, coronary artery bypass grafting; Comb, combined 
procedure (CABG +/− valve replacement, reconstruction); CPB, cardiopulmonary bypass; IABP, intra-aortic 
balloon pump. Please note that Eris et al. studied 3 subgroups vs. placebo (2 subgroups without a bolus but with 
a continuous infusion, 1 subgroup with bolus and continuous infusion post-CPB weaning) and Lomivotorov et 
al. studied 2 subgroups vs. IABP (both with bolus and continuous infusion).
Metainformation N Median (Range) N (%)
Year of publication 16 2012 (2006, 2016)
Study type 16
   RCT 14 (88)
   Retrospective study 1 (6)
   Case-control study 1 (6)
Surgery 16
   CABG 8 (50)
   Combined procedure 8 (50)
Comparator to levosimendan 16
   Placebo 13 (81)
   IABP 2 (13)
   nitrogycerine 1 (6)
Time point of levosimendan 
bolus 19*
   Pre-surgery 12 (63)
   Post-CPB weaning 1 (5)
   No bolus 6 (32)
Time point for levosimendan 
infusion 19*
   Pre-surgery 15 (79)
   During CPB weaning 1 (5)**
   No infusion 3 (16)
Table 2. Summary of metadata of studies included in meta-analysis. Legend: RCT, randomized controlled trial; 
CABG, coronary artery bypass grafting; IABP, intra-aortic balloon pump; CPB, cardiopulmonary bypass. * 
The meta-analysis includes 16 (main) studies with 19 subgroups for different levosimendan treatment strategy. 
** In the study of Eris et al. a subgroup of 10 patients received levosimendan during CPB weaning. Values are 
number, N; number and percent, N(%) or median with lower and upper quartile, median (lq, uq).
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A sensitivity analysis with correction of the standardized mean difference (SMD) in hemodynamic parameters 
at baseline was conducted to reduce heterogeneity in the baseline parameters collected by the included studies.
Methods
This analysis included randomized controlled trials (RCTs), retrospective and case-control studies providing 
appropriate hemodynamic datasets from adult patients undergoing cardiac surgery with CPB, and being treated 
with levosimendan vs. a comparator. The manuscript contains all data and complies with Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations (Fig. 2, Supplements A1 and A2)19.
Search strategy and eligibility criteria. Literature sources allowing unrestricted access to full texts and 
supplements in the US National Library of Medicine database (PUBMED), MEDLINE, EMBASE, and CENTRAL 
were searched systematically from 2006 until July 2018. Medical Subject Headings terms and free words refer-
ring to levosimendan in cardiac surgery were used as key words, including the following: levosimendan, car-
diac surgery, cardiopulmonary bypass OR levosimendan OR milrinone OR dobutamine OR nitroglycerine OR 
intra-aortic balloon pump OR mechanical circulatory support AND cardiac surgery, cardiopulmonary bypass 
and weaning from cardiopulmonary bypass.
Figure 3. Results of the Newcastle-Ottawa Scale for evaluation of risk of bias and quality of studies included in 
the meta-analysis. Studies with nine stars have a low risk of bias (high quality), seven or eight stars a medium 
risk (moderate quality), and six or less a high risk of bias (low quality).
Levosimendan Comparator
N Median (lq, uq) N Median (lq, uq)
No. of patients 16 18 (10, 127) 16 16 (10, 125)
Age (yrs) 16 65 (50, 76) 16 63 (46, 75)
Ejection fraction (%) 16 39 (18, 63) 15 43 (22, 69)
Perfusion time (min) 15 106 (73, 177) 15 122 (74, 185)
AoX time (min) 13 72 (43, 140) 13 74 (44, 137)
LOS ICU (hrs) 10 57 (25, 199) 10 53 (26, 182)
LOS Hospital (hrs) 12 271 (52, 631) 12 288 (98, 448)
Table 3. Summary of baseline characteristics. Legend: AoX, aortic cross clamp; LOS, length of stay, ICU, 
intensive care unit. Values are number, N and median with lower and upper quartile (lq, uq).
5Scientific RepoRtS |         (2019) 9:20343  | https://doi.org/10.1038/s41598-019-56831-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Key words were chosen by two authors on the basis of their own experience and other articles on similar 
topics. The reference lists of all selected papers were also screened for relevant studies. Eligibility criteria were: 
(a) English-language literature published from 2006 to October 2018, (b) study design (RCT, retrospective and 
case-control studies), (c) adult patient population, (d) cardiac surgery with CPB, (d) availability of at least two 
sequentially measured hemodynamic variables for the perioperative period, (e) levosimendan administration 
as a bolus and/or a continuous infusion before starting CPB, also including study subgroups with levosimendan 
administration as a bolus and/or a continuous infusion during CPB weaning, and (f) comparison of levosime-
ndan to another drug or device.
Study selection and data extraction. Two authors independently screened the titles and abstracts of 
the selected studies. Articles were excluded if they: (a) were not original research (e.g., case reports, editorials, 
reviews, congress abstracts), (b) did not provide at least two hemodynamic variables in the full-text version or in 
the supplement, (c) started levosimendan exclusively after cardiac surgery (after CPB weaning, post-operatively 
on the intensive care unit, ICU) and (d) were a duplicate. In cases where the article reported on hemodynamic 
variables without providing them as numbers (mean or median), the corresponding author was contacted for the 
original data set.
The full text versions of the articles selected by one or more of the assessors were retrieved for evaluation. Two 
assessors read the full texts and independently extracted the information from the selected studies. A third asses-
sor reviewed the data extraction, and any disagreement was resolved through consensus.
Assessment of risk of bias. The quality of the studies was evaluated with the Newcastle Ottawa Scale20. 
Two authors independently rated each study, and consensus discussion was used to resolve any dis-agreement.
Statistical analysis. Sixteen studies were included in this meta-analysis. One study had three different lev-
osimendan groups and another study had two different levosimendan groups. Both studies were compared only 
to one control group. We thus collapsed the hemodynamic endpoints of the levosimendan groups for these two 
studies, taking the mean of means, and the mean of the square-root of the sum of squares of standard deviations. 
For non-parametric results, we calculated the mean from the median, the lower quartile and the upper quartile, 
and the standard deviation from lower quartile, upper quartile and the number of patients, according to Wan and 
co-workers21. As our primary analysis, we calculated Hedges’ g as the standardized mean differences in order to 
meta-analyze endpoints among studies using the R package meta22. We calculated a separate meta-analysis for 
each endpoint and period. For sensitivity analysis we used multivariate mixed effects linear meta-analysis mod-
els, using time (baseline, a period (I) from baseline to 24 hours (inclusive) after surgery, and a period (II) from 
24 hours to 7 days after surgery) as a moderator, and the individual studies as random effect, using the R package 
metafor23. We used this model to correct the standardized mean difference (SMD) at period (I), or at period (II) 
after surgery by the SMD at baseline. All analyses were performed using R version 3.5.024. Values are numbers and 
percentages (n, %), or median with lower and upper quartile (m [lq, uq]).
Baseline 24 hours post surgery 7 days post surgery
N SMD (95% CI) p-value N SMD (95% CI) p-value N SMD (95% CI) p-value
Cardiac index 10 −0.08 (−0.30 to 0.14) 0.49 9 0.60 (0.38 to 0.82) <0.001 8 0.61 (0.15 to 1.07) 0.009
Central venous pressure 7 0.10 (−0.16 to 0.36) 0.44 8 −0.26 (−0.53 to 0.01) 0.05 7 −0.44 (−0.89 to 0.01) 0.05
Ejection fraction 14 −0.16 (−0.40 to 0.08) 0.20 2 −0.36 (−0.94 to 0.23) 0.23 3 −0.34 (−1.18 to 0.50) 0.43
Mean arterial pressure 9 −0.00 (−0.21 to 0.20) 0.97 9 −0.10 (−0.42 to 0.23) 0.56 8 0.10 (−0.30 to 0.50) 0.63
Pulmonary capillary 
wedge pressure 10 −0.00 (−0.20 to 0.19) 0.96 10 −0.28 (−0.51 to −0.05) 0.02 7 −0.32 (−0.66 to 0.02) 0.06
Systemic vascular 
resistance/-index 9 −0.13 (−0.34 to 0.08) 0.21 8 −0.42 (−0.67 to −0.16) 0.001 7 −0.40 (−0.63 to −0.17) <0.001
Table 4. Number of studies, standardized mean difference and p-values of random effects meta-analyses 
for every outcome and all three time points. N, number, SMD standardized mean difference CI, confidence 
intervall.
SMD (95% CI) p-value SMD (95% CI) p-value
Cardiac index 0.74 (0.24 to 1.23) 0.003 0.75 (0.25 to 1.25) 0.003
Central venous pressure −0.31 (−0.92 to 0.30) 0.32 −0.50 (−1.12 to 0.11) 0.11
Ejection fraction 0.23 (−0.56 to 1.02) 0.57 0.21 (−0.44 to 0.85) 0.53
Mean arterial pressure −0.18 (−0.67 to 0.31) 0.47 0.14 (−0.36 to 0.64) 0.58
Pulmonary capillary wedge pressure −0.32 (−0.78 to 0.14) 0.18 −0.34 (−0.81 to 0.13) 0.16
Systemic vascular resistance/-index −0.17 (−0.64 to 0.30) 0.48 −0.13 (−0.61 to 0.34) 0.58
Table 5. Standardized mean difference at 24 hours and 7 days post-surgery, corrected for the standardized 
mean difference at baseline, calculated by a multivariate mixed effects meta-analysis model with the time as 
moderator and the study as random effect. Legend: SMD standardized mean difference CI, confidence intervall.
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Results
Description of studies. The final analysis included 16 studies (14 RCTs, 1 retrospective study and 1 case-
matched study) with 1071 patients overall (Table 1). Coronary artery bypass grafting (CABG) and combined 
procedures (CABG and valve repair/replacement) were equally represented. The most common comparator to 
levosimendan was placebo (n = 13, 81%). In the majority of 19 subgroups levosimendan was administered as a 
pre-operative bolus of 12 mcg/kg [3, 200] and was followed by a continuous infusion of 0.1 mcg/kg/min [0.05, 
0.2] (Table 2).
Risk of bias and the quality of the studies was assessed by using The Newcastle-Ottawa Scale (Fig. 3).
Description of populations. Age and number of patients were the only baseline characteristics available 
in all studies. The least frequently reported characteristic was length of stay in the intensive care unit. Across all 
studies, baseline characteristics were similar between the levosimendan and the comparator groups (Table 3).
Figure 4. Forest plots for cardiac index: (a) at baseline, (b) during period (I) and (c) during period (II).
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primary analysis. Reporting of endpoints differed widely among the studies and between the time points. 
The most frequently reported endpoints were cardiac index and pulmonary capillary wedge pressure. Mean arte-
rial pressure was reported in nearly two thirds of the studies. Systemic vascular resistance was reported either as 
non-indexed (SVR) or indexed to body surface area (SVRI). Inclusion or exclusion of the studies reporting SVR 
(study number 6, 9, 16, Table 1) did not change the results of the sensitivity analysis. Thus, the manuscript reports 
the results obtained from all studies as SVR.
Central venous pressure and ejection fraction were the least frequently reported endpoints, although ejection 
fraction was reported in nearly all studies at baseline.
At baseline, none of the endpoints differed between the two groups. Within the first 24 hours postoperatively, 
levosimendan increased cardiac index, and decreased pulmonary capillary wedge pressure and SVR. This pattern 
prevailed until postoperative day (POD) 7, when a higher cardiac index and lower SVR were reported for patients 
Figure 5. Forest plots for systemic vascular resistance: (a) at baseline, (b) during period (I) and (c) during 
period (II).
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with levosimendan than for patients treated with comparators. All other endpoints did not differ between patients 
receiving levosimendan and those from the comparison group (Table 4).
Sensitivity analysis. The mixed effects model meta-analysis, corrected for the standardized mean difference 
at baseline, confirmed most results from the primary analysis. Cardiac index increased significantly from base-
line to later time periods. The other endpoints did not change significantly from baseline to the two later periods 
(Table 5). In sensitivity analysis, the difference of SVR between levosimendan and comparators, as described in 
the primary analysis section, became insignificant due to the correction for baseline differences.
Forest plots for cardiac index and systemic vascular resistance at baseline (a), and during periods (I) and (II) 
are given in Figs. 4 and 5. Forest plots for central venous pressure, ejection fraction, mean arterial pressure, pul-
monary capillary wedge pressure b) during period (I) and (II) are presented in the Figs. 6, 7, 8 and 9.
Discussion
The present systematic review and meta-analysis showed a similar pattern of hemodynamic changes across the 
different studies when levosimendan was prophylactically administered to adult patients undergoing cardiac sur-
gery with CPB. During the first postoperative week, levosimendan increased cardiac index when compared to 
the respective comparator, whereas its use was not associated with significant reduction of systemic vascular 
resistance in the context of postoperative care in the studies.
During the past decade, 72 meta-analyses have been published on levosimendan in various settings, with focus 
on mortality, neurohormones, troponin release, renal function, length of hospital stay, pharmaco-economics etc. 
Figure 6. Forest plots for central venous pressure: (a) at baseline, (b) during period (I) and (c) during period 
(II).
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None of these meta-analyses focused specifically on perioperative endpoints of the hemodynamic profile. The 
positive inotropic action with associated increase of cardiac output, stroke volume, and ejection fraction is a 
well-known pharmacodynamic property of levosimendan and represents the main indication for the use of lev-
osimendan in cardiac surgery.
Almost all studies included in this current meta-analysis showed an increase in cardiac index. The RCT by 
Lomivorotov showed the largest effect, with increases in cardiac index at 24 hours and 7 days after cardiac sur-
gery7. This may be due to the selective inclusion of patients with low preoperative ejection fraction (<35%), 
and/or to the use of IABP in addition to levosimendan in a subgroup of patients. The use of IABP may have 
had an additional positive effect on coronary perfusion, and hence cardiac performance. Similarly, the RCTs of 
Anastasiadis25 and Atalay26 observed increases in cardiac index 24 hours and 7 days after cardiac surgery. Both 
studies, however, included only patients with mild or moderate left ventricular dysfunction undergoing CABG. In 
the retrospective study of Eris, the positive inotropic effect of levosimendan was still apparent at the time points of 
observation, however with a reduced fixed weight, mainly owing to the small subgroups (n = 10) and widely vary-
ing modalities of levosimendan administration27. Also, not all studies could confirm stimulatory effects of levosi-
mendan on cardiac index with a weighting similar to other studies. Two small RCTs failed to observe a beneficial 
effect of levosimendan on cardiac index at their RCT’s last hemodynamic assessment point28,29. Reasons for this 
may be the small size and/or non-homogeneity of their samples, such as groups already differing in baseline EF28 
or in the rate of post-CPB institution of mechanical circulatory support29. Also, in both studies levosimendan was 
started rather late and slowly, i.e., after anesthesia induction and without bolus, which probably delayed the onset 
of the drug’s inotropic action. A potential between-group difference in cardiac index may have been levelled out 
in the study of Järvelä by the significantly higher noradrenaline dosage, and hence afterload, in the levosimendan 
group28. In the RCT of Erb, the more frequent use of IABP and ventricular assist devices in the control group may 
have masked superior hemodynamic effects of levosimendan in comparison with placebo29.
Figure 7. Forest plots for ejection fraction: (a) at baseline, (b) during period (I) and (c) during period (II).
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Systemic arterial vasodilation is a genuine though often undesired effect of levosimendan, since it may be asso-
ciated with relevant reductions in mean arterial pressure and total peripheral resistance6,9,30. Although no studies 
have documented increased mortality which could be causally related to levosimendan-associated hypotension28,31, 
marked arterial hypotension is undesirable during or after cardiac surgery since it may compromise end-organ per-
fusion32–34. In contrast to the primary analysis of our study, which showed a significant decrease of SVR until the 
seventh postoperative day, our sensitivity analysis did not confirm a significant difference in the SVR between patients 
treated with levosimendan and those receiving comparators. While the primary analysis focused on SVR difference 
between levosimendan and the comparison group at each time point, secondary analysis corrected for baseline dif-
ferences. Thus, the lower SVR in the levosimendan group described by the primary analysis is due to a pre-existing 
baseline difference. In this context, it is conceivable that, especially in patients with preoperative IABP use, a decreased 
SVR was measured due to an afterload reduction. However, since our secondary analysis was corrected for baseline 
differences and no significant difference between levosimendan and comparator groups could be demonstrated in the 
further perioperative course, we assume that SVR reduction by IABP is not relevant in this setting.
Low SVR in association with the use of levosimendan in critically ill patients is frequently reported in the 
clinical literature, as well as in studies included in the present meta-analysis. However, there are discrepancies. 
Severi reported higher systemic vascular resistance in their levosimendan group when comparing it with a 
control group treated solely by prophylactic placement of IABP35. Starting study drug infusion 24 hours prior 
to surgery, Anastasiadis found no significant difference in SVR or MAP between their levosimendan and pla-
cebo groups until 24 hours postoperatively25. Similarly, the large randomized, placebo-controlled clinical trials 
CHEETAH36, LICORN37, and LEVO-CTS38 did not demonstrate an increased incidence of hypotension as an 
Figure 8. Forest plots for mean arterial pressure: (a) at baseline, (b) during period (I) and (c) during period (II).
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adverse event. The reasons for such discrepancies are not fully understood, but may be related to a diminished 
dose-dependent effect on KATP channels in vessels with low resistance when levosimendan infusion commences 
early in the pre-operative period, typically between 12 and 24 hours prior to CPB. Another explanation may be 
the rather moderate dosage of continuous levosimendan infusions (0.05–0.1 mcg/kg/min) in the respective stud-
ies or different compensatory dosages of vasopressor drugs.
The main limitation of the present study comes from missing information and inconsistencies in the reporting 
of hemodynamic data in the studies analyzed. Other common limitations, intrinsic in meta-analyses, are the het-
erogeneity of patient populations with different etiologies and stages of heart failure and comorbidities, different 
types of cardiac surgery (coronary artery bypass grafting vs. valve surgery) in the studies analyzed and the large 
variety of clinical and research protocols, which differ, for example, in terms of levosimendan dosage, adminis-
tration regimens, comparators and combination therapies, with concomitant use of catecholamines, vasoactive 
drugs and mechanical circulatory support devices.
In conclusion, this meta-analysis and systematic review confirms that perioperative treatment with levosim-
endan improves cardiac index in adult patients undergoing cardiac surgery with CPB. As a new aspect, however, 
this current review finds no clinical evidence that levosimendan produces vasopressor-resistant vasoplegic syn-
drome. Thus, objections to the use of levosimendan in cardiac surgery appear unjustified if they are based solely 
on the fear of triggering postcardiotomy vasoplegic syndrome.
Received: 26 July 2019; Accepted: 16 December 2019;
Published: xx xx xxxx
Figure 9. Forest plots for pulmonary capillary wedge pressure: (a) at baseline, (b) during period (I) and (c) 
during period (II).
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